Muscle Spasticity Pipeline Drugs and Companies Insight Repor...| MENAFN.COM

Monday, 17 January 2022 10:03 GMT

Muscle Spasticity Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

(MENAFN- GetNews) “Muscle Spasticity Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Muscle Spasticity market. A detailed picture of the Muscle Spasticity pipeline landscape is provided, which includes the disease overview and Muscle Spasticity treatment guidelines.

DelveInsight's “Muscle Spasticity Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Muscle Spasticity pipeline landscapes. 

The report comprises Muscle Spasticity pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Muscle Spasticity therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Muscle Spasticity pipeline products.   


Muscle Spasticity Overview

Spasticity is defined as“sensorimotor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex” or from an upper motor neuron lesion (UMN), presenting as intermittent or sustained involuntary activation of muscles. The region and the extent of impairment depending on the area of the brain or spinal cord that has been damaged. It can occur in the upper and/or lower limbs.

Some of the key takeaways from the Muscle Spasticity Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as GW Pharmaceuticals, Revance Therapeutics, Ipsen, etc., are developing therapies for the treatment of Muscle Spasticity.

  • Emerging therapies such as Nabiximols, DAXI, IPN10200, are expected to have a significant impact on the Muscle Spasticity market in the coming years.

Get an overview of pipeline landscape @ Muscle Spasticity Clinical Trials Analysis 

Muscle Spasticity Pipeline Therapies along with Key Players:

  • Nabiximols: GW Pharmaceuticals

  • DAXI: Revance Therapeutics

  • IPN10200: Ipsen

Scope of Muscle Spasticity Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: GW Pharmaceuticals, Revance Therapeutics, Ipsen, and others.

  • Pipeline Therapies: Nabiximols, DAXI, IPN10200, and others.

Table of Contents


Muscle Spasticity Report Introduction


Muscle Spasticity Executive Summary


Muscle Spasticity Overview


Muscle Spasticity- Analytical Perspective In-depth Commercial Assessment


Muscle Spasticity Pipeline Therapeutics


Muscle Spasticity Late Stage Products (Phase II/III)


Muscle Spasticity Mid Stage Products (Phase II)


Muscle Spasticity Early Stage Products (Phase I)


Muscle Spasticity Preclinical Stage Products


Muscle Spasticity Therapeutics Assessment


Muscle Spasticity Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Muscle Spasticity Key Companies


Muscle Spasticity Key Products


Muscle Spasticity Unmet Needs


Muscle Spasticity Market Drivers and Barriers


Muscle Spasticity Future Perspectives and Conclusion


Muscle Spasticity Analyst Views




About DelveInsight

Get a customized pipeline report @ Muscle Spasticity Drugs Pipeline Report


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.